RxDoctor Payments Data

Samantha Wideman, APRN

Nurse Practitioner · Hot Springs, ARNPI 1952052243

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,389 of the $13,758 with a category attached, or 82.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,758in general payments, 2019–2025

Across 610 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$2K
  • Novartis$1K
  • AstraZeneca$762
  • Exelixis Inc.$752
  • Pfizer$702
  • Johnson & Johnson$625
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1351%
  • Speaking & faculty fees$1,2749%
  • Travel & lodging$4663%
  • Food & beverage$11,38983%
  • Education$4954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacosmos Therapeutics Inc.13$1,994
Novartis92$1,313
AstraZeneca(2 entities)31$762
Exelixis Inc.30$752
Pfizer41$702
Johnson & Johnson(2 entities)34$625
Merck32$551
Eisai Inc.19$486
Incyte Corporation20$463
GSK23$432
AbbVie18$382
Takeda Pharmaceuticals U.S.A., Inc.14$367
Daiichi Sankyo Inc.15$337
Sanofi13$286
Bristol Myers Squibb19$253
Gilead13$241
Seagen Inc.14$230
Regeneron Healthcare Solutions, Inc.8$204
Lilly USA, LLC11$175
Bayer8$174
Morphosys, US Inc.8$151
Sobi, Inc8$150
Mirati Therapeutics, Inc.7$129
Amgen9$127
Otsuka America Pharmaceutical, Inc.1$125
Astellas Pharma US Inc7$112
Array Biopharma Inc6$111
Biohaven Pharmaceutical Holding Company Ltd.1$108
Karyopharm Therapeutics Inc.1$107
Sirtex Medical Inc1$105
E.r. Squibb & Sons, L.L.C.6$101
Beone Medicines USA, Inc.5$97
Beigene USA, Inc.5$97
Adaptive Biotechnologies Corporation2$96
Sanofi-aventis U.S. LLC1$95
AVEO Pharmaceuticals, Inc.5$80
Shield Therapeutics Inc5$79
Celltrion USA Inc.4$76
Stemline Therapeutics Inc.4$75
EMD Serono, Inc.4$74
Spectrum Pharmaceuticals Inc.4$72
Pharmacyclics LLC, An Abbvie Company4$65
Geron Corporation3$60
Myriad Genetic Laboratories, Inc.3$56
Pharmaessentia USA Corporation3$56
Ipsen Biopharmaceuticals, Inc3$55
Iovance Biotherapeutics, Inc.2$54
Dendreon Pharmaceuticals LLC2$53
Puma Biotechnology, Inc.3$50
Rigel Pharmaceuticals, Inc.3$46
Blueprint Medicines Corporation2$45
Boehringer Ingelheim2$40
Acrotech Biopharma Inc.2$33
CTI Biopharma Corp.2$32
Jazz Pharmaceuticals Inc.2$30
Genentech USA, Inc.2$27
G1 Therapeutics, Inc.2$26
Tersera Therapeutics LLC1$23
Apellis Pharmaceuticals, Inc.1$20
Heron Therapeutics, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,758 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$32,515
Medicare patients
152
Services billed
878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate14$200,294
EliquisApixaban30$25,137
XareltoRivaroxaban13$12,287
Exemestane13$1,227
Anastrozole39$711
Tamoxifen Citrate19$655
Letrozole25$571
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)26$449
Pantoprazole Sodium11$185
Levothyroxine Sodium23$176
Prednisone20$108
Dexamethasone14$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$463$200,29414 claims
PfizerEliquis$702$25,13730 claims
Johnson & JohnsonXarelto$625$12,28713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →